|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2007-5-21
|
|
pubmed:abstractText |
To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AbramsJudithJ,
pubmed-author:AronsonFrederick RFR,
pubmed-author:AtkinsMichael BMB,
pubmed-author:CostanziJohn JJJ,
pubmed-author:Das GuptaTapas KTK,
pubmed-author:DeContiRonald CRC,
pubmed-author:DeisserothAlbert BAB,
pubmed-author:DudekArkadiusz ZAZ,
pubmed-author:ErnstoffMarc SMS,
pubmed-author:HaluskaFrank GFG,
pubmed-author:HwuWen-JenWJ,
pubmed-author:JakowatzJames GJG,
pubmed-author:JonesVicky EVE,
pubmed-author:Kashani-SabetMohammedM,
pubmed-author:MitchellMalcolm SMS,
pubmed-author:RichardsJon MJM,
pubmed-author:SamlowskiWolfram EWE,
pubmed-author:ThompsonJohn AJA,
pubmed-author:WhitmanEricE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2078-85
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17513813-Cancer Vaccines,
pubmed-meshheading:17513813-Combined Modality Therapy,
pubmed-meshheading:17513813-Cytoskeletal Proteins,
pubmed-meshheading:17513813-Dose-Response Relationship, Drug,
pubmed-meshheading:17513813-Drug Combinations,
pubmed-meshheading:17513813-Female,
pubmed-meshheading:17513813-Follow-Up Studies,
pubmed-meshheading:17513813-Humans,
pubmed-meshheading:17513813-Immunotherapy, Active,
pubmed-meshheading:17513813-Interferon-alpha,
pubmed-meshheading:17513813-Lipid A,
pubmed-meshheading:17513813-Lymphatic Metastasis,
pubmed-meshheading:17513813-Male,
pubmed-meshheading:17513813-Melanoma,
pubmed-meshheading:17513813-Middle Aged,
pubmed-meshheading:17513813-Neoplasm Recurrence, Local,
pubmed-meshheading:17513813-Recombinant Proteins,
pubmed-meshheading:17513813-Skin Neoplasms,
pubmed-meshheading:17513813-Survival Rate
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
|
|
pubmed:affiliation |
University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA. malcolmsmitchell@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
